Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Foundation Medicine And Clovis Oncology Enter Into Diagnostic Collaboration

RELATED NEWS
Trade CLVS now with 
8/6/2012 7:23 AM ET

Foundation Medicine Inc. and Clovis Oncology Inc. (CLVS: Quote) announced that they have entered into a diagnostic collaboration. The company said that the goal of the collaboration is to develop an in-vitro diagnostic or IVD to identify biomarkers to select cancer patients most likely to respond to Clovis' product candidate rucaparib, a poly (ADP-ribose) polymerase or PARP inhibitor currently in Phase I/II clinical development.

Clovis Oncology said that the company and Foundation Medicine will analyze the genomic alterations found in tissue samples from patients to evaluate the feasibility of developing an IVD method to identify patients who have tumors more likely to respond to rucaparib.

In particular, the goal of the collaboration is to identify the additional genetic mutations beyond those in germ-line and somatic BRCA that are associated with defective DNA repair and may define appropriate tumor targets for rucaparib.

Click here to receive FREE breaking news email alerts for Clovis Oncology, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Starbucks Corp. said Thursday after the markets closed that its second quarter profit rose 9.4% from last year, helped by higher revenue. The company's quarterly earnings per share came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. The world's largest specialty coffee retailer also raised its full year earnings outlook. Software giant Microsoft Corp. said Thursday after the markets closed that its third quarter profit fell 6.6% from last year, when results were boosted by special upgrade offer revenues. However, the company's quarterly earnings per share came in above analysts' expectations as did its quarterly revenue. Apple Inc. said Wednesday after the markets closed that its second quarter profit rose 7% from last year, as sales surged and margins improved amid strong sales of its iPhones. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue. At the same time, the company gave a slightly downbeat revenue forecast for the current quarter.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.